RNAi Technology Market
RNAi Technology Market Scope: Industry Analysis, Market Size, Growth, Trends Till 2031
Request Sample Report
RNAi Technology Market Size and Growth
The RNAi technology market is experiencing significant growth, driven by advances in therapeutic applications and increased research funding. The global market size is projected to reach approximately $5 billion by 2026, reflecting a compound annual growth rate of over 15%. Key factors include rising disease prevalence and innovative delivery methods.
Request Sample Report
Companies Covered
(Covid 19 Impact Covered)
◍ Alnylam Pharmaceuticals
◍ Dicerna Pharmaceuticals, Inc.
◍ Arrowhead Pharmaceuticals, Inc.
◍ Ionis Pharmaceuticals, Inc.
◍ Quark Pharmaceuticals, Inc.
◍ Arbutus Biopharma
◍ Benitec Biopharma
◍ Calando
◍ Silence Therapeutics
◍ Gotham Therapeutics
The RNAi technology market features companies like Alnylam Pharmaceuticals and Dicerna, pioneering RNAi therapies. Alnylam's Onpattro leads in sales, while Arrowhead focuses on hepatitis B. Ionis innovates with antisense technologies. These firms drive market growth through novel therapeutics, strategic partnerships, and advancing RNAi applications in diverse diseases, collectively increasing market value.
**Sales Revenue Highlights:**
- Alnylam Pharmaceuticals: $200 million (2022)
- Ionis Pharmaceuticals: $400 million (2022)
- Arrowhead Pharmaceuticals: $86 million (2022)
Request Sample Report
Market Segmentation
By Application
Drug Discovery & Development
Therapeutics
Drug Delivery
By Product
◍ Cancer
Liver Disorders
Respiratory Disorders
Others Request Sample Report
Neurological Disorders
Autoimmune Disorders
Others
Market Growth
Request Sample Report
$ 37.59 Billion
